Simons Searchlight
X
  • About Us
    • Our Mission
    • Our Participants
    • Simons Searchlight Staff
    • Community Advisory Committee
    • SFARI Programs
  • Research
    • For Scientists
    • Genes We Study
    • Research Process
    • Data & Biospecimens
    • Participating in Other Languages
    • Research Match
  • News
  • Resources
    • Frequently Asked Questions
    • Outreach Toolkit
    • Newsletters
    • Video Library
    • Publications
    • Navigating Life After a Rare Genetic Diagnosis
    • Resource Links
    • COVID-19
      • COVID-19 Vaccine Statement
      • COVID-19 Infection and NDD
      • Caregiver Support
      • Medical Emergency Card
      • Survey Summary
      • Survey 2 Summary
      • Survey 3 Summary
      • Survey 4 Summary
      • Survey 5 Summary
      • Survey 6 Summary
  • Contact Us
  • Join Us
  • Login
X
">

GRIN2A mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine< /strong> < /h2>

Original research article by T.M. Pierson et al. < /em> (2014) < /p>

Read the article here< /a> . < /p>

The  GRIN2A    < /em>gene encodes for proteins that are linked to signaling pathways in the brain. These proteins have an important role in brain development, learning and memory, and signaling within the brain.   GRIN2A  has been associated with diagnoses of epilepsy, developmental delay, and intellectual disability. < /p>

In this article, researchers describe one child with a  de novo  change (a change not found in either parent) in the  GRIN2A gene. Identified through the National Institutes of Health (NIH) Undiagnosed Diseases program, the 6-year-old boy had a history of early-onset epileptic encephalopathy and profound global developmental delay, having not reached any developmental milestones. He was reported to have daily seizures that did not respond to medication. His brain MRI showed a loss of volume and brain tissue. < /p>

The researchers suggest that the change in GRIN2A has hindered the ability of the proteins associated with  the gene  to function properly. The study suggests that it may be reasonable to consider a broad genetic test, such as whole-exome sequencing, to analyze genes not typically included in targeted panels. < /p>

searchlight
  • About
  • Research process
  • Resources
policies
  • Terms of Use
  • Privacy
  • Study Information
simons foundation
  • SFARI
  • SPARK
  • Spectrum
  • Simons Foundation
support
  • Contact Us
  • Frequently Asked Questions
This page was originally written in English. Simons Searchlight cannot guarantee the accuracy of third-party translations.
Simons Searchlight | © 2023 Simons Foundation
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
We care about your data, and we'd like to use cookies to give you a smooth browsing experience. Please agree and read more about our privacy policy.AGREE